Use of Diuretics for Bronchopulmonary Dysplasia Increases Metabolic Bone Disease in Preterm Infants

Objective: Preterm infants (PI) are at increased risk of developing metabolic bone disease (MBD).This study assessed the association diuretics for bronchopulmonary dysplasia (BPD) with MBD. Study Design: This retrospective included ≤30 weeks gestation and birth weight ≤1500 grams. Infants were divided into diuretic group control group. Diuretic use was defined as hydrochlorothiazide spironolactone >7 days MBD PTH >100 mg/dL. Data analyzed using SPSS p <0.05 considered significant. Results: The 201 infants, a mean gestational age 26.31 ± 1.73 weeks. There 68 (33%) in vs. 133 (67%) 41 24% (p<0.05) who received BPD also developed 80% 20% (p<0.001) treated diuretics. Diuretics did not improve respiratory status these PI. We found given remained on ventilation longer total number (p<0.001). Conclusion: PI more likely to develop without any significant improvement